Does Ceftin Cover Proteus mirabilis?
Yes, cefuroxime (Ceftin) does provide coverage against Proteus mirabilis, though susceptibility patterns vary and resistance has been documented.
Microbiological Activity
Cefuroxime demonstrates activity against Proteus mirabilis based on multiple lines of evidence:
In vitro susceptibility studies from 1979-1987 consistently showed that P. mirabilis isolates were sensitive to cefuroxime, with one study reporting that "all the isolates of Proteus mirabilis were sensitive to cefuroxime" 1. Historical comparative data showed cefuroxime was superior to older cephalosporins like cephalothin against P. mirabilis 2.
Contemporary resistance patterns indicate evolving susceptibility. A 2016 study examining pneumonia pathogens found that while P. mirabilis showed high resistance to tetracycline (100%) and ampicillin (55%), the overall resistance profile suggests variable susceptibility to second-generation cephalosporins 3.
Documented resistance mechanisms exist: A 1991 study identified a plasmid-mediated beta-lactamase (FPM-1) in a cefuroxime-resistant P. mirabilis clinical isolate, demonstrating that resistance can develop and be transferable 4.
Clinical Considerations
For urinary tract infections specifically, cefuroxime shows favorable pharmacokinetics since it is predominantly excreted unchanged in urine. Recent pharmacokinetic modeling (2025) demonstrated that cefuroxime axetil 250 mg twice daily achieves 100% probability of target attainment for MIC values up to 8 mg/L in urinary tract infections 5. A 2022 study of P. mirabilis UTIs in patients with urinary calculi found variable seasonal sensitivity to cefuroxime, with significantly higher rates in winter 6.
For systemic infections, the evidence is more limited. While cefuroxime has been used successfully in pyelonephritis treatment 7, and historical data supports its activity against P. mirabilis 8, third-generation cephalosporins like cefotaxime showed "marked advantages with respect to various Proteus species" compared to cefuroxime 1.
Important Caveats
- Susceptibility testing is essential before definitive therapy, as resistance patterns vary geographically and temporally
- P. mirabilis is generally more susceptible than other Proteus species (P. vulgaris, P. penneri), which show higher resistance rates to second-generation cephalosporins 1
- Resistance is more common in urogenital infections compared to other infection sites 1
- Consider local antibiograms and resistance patterns when selecting empiric therapy
Bottom line: Cefuroxime provides coverage against many P. mirabilis strains, particularly for urinary tract infections, but susceptibility testing should guide definitive therapy due to documented resistance mechanisms and variable regional patterns.